←
Greco Mark Malijan13,404 posts
Greco Mark Malijan avatar

Greco Mark Malijan

@grecombm

@Oxford_NDPH Renal Studies Group DPhil student @StEdmundHall #EMPAKIDNEY | Advocate for LARGE & randomised trials | he/him

◷ Joined July 2011▧ 511 Photos and videos
Medical Sciences avatar
⟳ Greco Mark Malijan retweeted
Medical Sciences@OxfordMedSci·Oct 19

NEWS: Welcome to the new Regius Professor of Medicine Prof Menna Clatworthy’s career has focused on immunology and nephrology. She is known for her influential work in tissue and humoral immunity and we look forward to welcoming her to the division. ox.ac.uk/news/2026-10-16-pro…

Post attachment
sententiae antiquae avatar
⟳ Greco Mark Malijan retweeted
sententiae antiquae@sentantiq·Oct 2

Stop anthropomorphizing computer programs while dehumanizing actual people challenge

Pope Leo XIV avatar
⟳ Greco Mark Malijan retweeted
Pope Leo XIV@Pontifex·Oct 2

In this era of artificial intelligence, it is becoming urgent to distinguish human art from what machines produce. There is an ontological difference, even before an aesthetic one, between art and what a machine can generate through statistical calculation based on millions of images created by others. Algorithms lack the spark of humanity. For this reason, the Church wishes to renew an alliance with artists and cultural institutions to safeguard our humanity.

Joel M. Topf, MD FACP avatar
⟳ Greco Mark Malijan retweeted
Joel M. Topf, MD FACP@kidney_boy·Sep 14

Hello NephJC community, NephJC is now over a dozen years old. When we started, the idea was pretty simple: get a bunch of nephrologists together on Twitter, pick an important paper, and argue about it in public. Somehow, that turned into something much bigger. NephJC became a place where nephrologists, fellows, residents, students, researchers, and patients could come together to understand the research and manuscripts moving nephrology forward. We built detailed article summaries, visual abstracts, podcasts, book clubs, tweetorials, and an internship designed to train the next generation of medical educators. And through all of it, we have tried to hold onto one basic principle: The education should be free. No subscriptions. No passwords. No paywalls. And no pharmaceutical sponsorship. Every year, big (and small) pharma offers to sponsor NephJC, or advertise at NephJC.com, or place an ad in @FreelyFiltered. It would make running NephJC much easier. We say no. In fact, our bylaws prevent us from accepting pharmaceutical support. Why? Because NephJC exists to critically evaluate the medical literature, including papers studying drugs made by those same companies. We believe accepting any support would at the very least create the perception of a conflict even if our hearts stayed true (which of course they would). That’s the hill we will die on. But independence isn’t free. Web hosting costs money. Podcasting costs money. Software costs money. Visual abstracts cost money. Running the NephJC Editorial Internship costs money. Keeping this entire unique experiment in post-publication peer review alive costs money. Over the years, we have funded NephJC in a lot of different ways. In the beginning, we passed the hat among the NephJC workgroup. Satellite Healthcare (RIP😢) was an early supporter. @ArkanaLabs gave us a generous three-year unrestricted grant. The Flozinator Pin (Flozinator.com) helped carry us through the pandemic. But for the last five years we have a simple model: NephJC is supported by the people who use NephJC. Wikipedia. Public radio. NephJC. You don’t need to donate to read a NephJC summary. You don’t need to donate to download a visual abstract. You don’t need to donate to listen to Freely Filtered or Channel Your Enthusiasm. And we are never going to put those things behind a paywall. But if NephJC has taught you something… If one of our summaries helped you understand a paper… If you’ve borrowed one of our visual abstracts for a lecture… If you’ve listened to the Filtrate argue about a trial while driving to work… If you’ve used NephJC to teach your fellows, residents, or students… Then we’re asking you to help pay for it. Not because you have to. Because that’s how we keep it independent. The alternative is easy. There is plenty of industry money available in nephrology. We choose the harder path because we think independent, critical, open medical education is worth protecting. If you agree, please support the 2026 NephJC Pledge Drive. Open your wallet. Open your purse. Skip one fancy coffee. Or give enough to buy us the whole coffee shop. Whatever makes sense for you. Thousands of people use NephJC. We don’t need every one of them to give a lot. We just need enough of them to give something. Keep the FOAMed flowing. Support NephJC. DONATE HERE: nephjc.com/news/2026/9/8/nep… Joel Topf President, NephJC

CEPI avatar
⟳ Greco Mark Malijan retweeted
CEPI@CEPIvaccines·Sep 1

It is with great sadness that CEPI received the news that Dr Vaseeharan Sathiyamoorthy, or Vasee Moorthy for short, passed away suddenly on 30 August 2026. He was the Strategy and Scientific Adviser in the Department of Science for Health and acting Lead of the R&D Blueprint for Epidemics in the Office of the Chief Scientist at WHO. CEPI’s Deputy CEO, Aurélia Nguyen, had the privilege of spending the past week with Vasee in the Democratic Republic of the Congo, as part of the WHO delegation led by Dr Chikwe Ihekweazu, observing the Ebola outbreak response and working together to advance preparations for vaccine clinical trials. It was a week of long days - airports, offices, bumpy roads, hours in the field - which provided an opportunity to talk at length about the work and the people behind it. Vasee was one of the most respected figures in the global research community. He was especially proud of his work designing the Phase 3 clinical trial for the malaria vaccine that ultimately secured licensure. Over seventeen years at WHO, he valued deeply that it was an institution where scientific advice could be given honestly and taken seriously. He spoke warmly of the wide community of researchers he convened and consulted throughout his career, and of how much he enjoyed that collaborative spirit. During the visit to Kinshasa and Bunia, Vasee’s overarching drive was to ensure the country had ownership of the research component of the response, in the two clinical trials for therapeutics under way and in the preparation for the vaccine clinical trials. Having clinical trial research capacity in lower-income countries was the theme that animated him through his whole career, whether for endemic diseases like malaria or in outbreak response for Ebola. Outside of work, Vasee was a passionate hiker who organised a weekly hiking group and chased a personal goal of doing a thousand metres of elevation every week. He was looking forward to the multi-day hike he took every September. He was also a loving husband and devoted father to his three children and spoke of his family often and with real pride. Vasee brought rigour, warmth, and an unmistakable enthusiasm to everything he did - for science, in the mountains, and for the people around him. This is deeply shocking and tragic news, he will be deeply missed by the many communities he was part of. Our thoughts are with his family at this time.

Post attachment
Edwine Barasa avatar
⟳ Greco Mark Malijan retweeted
Edwine Barasa@EdwineBarasa·Sep 1

Honoured to be appointed to the WHO Science Council, joining 20 leading scientists from around the world to help shape the future of science, research and innovation for global health. Grateful for the opportunity and excited about the work ahead. @WHO @KEMRI_Wellcome @TropMedOxford who.int/news/item/27-08-2026…

Roser Torra avatar
⟳ Greco Mark Malijan retweeted
Roser Torra@torra_roser·Aug 29

@ERAkidney is so proud of the nephrologists who were part of the Task Force behind the newly released 2026 @escardio Guidelines for the Management of Cardiovascular Disease in Patients with Chronic Kidney Disease. Congratulations to all involved in this important achievement! 🙌

Post attachmentPost attachmentPost attachmentPost attachment